SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform

 

SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization.

 

SEOUL, South Korea, Oct. 21, 2025  -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology worldwide, today announced the establishment of Mentis Care, Inc., a joint venture with a leading Brazil-based pharmaceutical company, Eurofarma, with presence in 24 countries, including North America, Latin America and Africa, to commercialize an AI-based epilepsy management platform. The company hosted a launching ceremony on October 20 (EDT) in Toronto, Canada, to celebrate its full-scale expansion into digital healthcare beyond its innovative drug development portfolio.

 

Executives celebrate the launch of Mentis Care, a joint venture established by SK Biopharmaceuticals and Eurofarma.

 

Since 2018, SK Biopharmaceuticals has built its proprietary expertise in AI-driven electroencephalography (EEG) and wearable device technologies with seizure detection and real-time monitoring. Mentis Care will leverage these technologies to develop a comprehensive digital platform that combines real-time seizure detection and prediction algorithms with clinical decision support tools, creating an integrated system for personalized patient care.

 

Mentis Care is located in the MaRS Discovery District in Toronto, Canada — one of North America's largest innovation hubs bringing research institutions, startups, and investors in life sciences and healthcare together. The company plans to expand its local team, strengthen academic and industry collaborations, and pursue clinical validation of its AI algorithms.

 

As a pharmaceutical company representing Latin America, Eurofarma leads business strategy planning and AI data learning of the venture. SK Biopharmaceuticals has collaborated with Eurofarma since 2022 to develop and commercialize its anti-seizure medication, cenobamate (U.S. brand name: XCOPRI®) in Latin America. The partnership extends into digital healthcare through the joint venture establishment.

 

Mentis Care has appointed Hassan Kotob, former Chief Executive Officer of Brain Scientific, as Chief Executive Officer (CEO). Kotob, a veteran healthcare and technology executive with a proven track record across high-growth and emerging technology companies, will lead Mentis Care's development of a first-of-its-kind, AI- and data-driven platform for predictive brain health — transforming how seizures and other neurological events are forecast and managed. 

 

"Mentis Care is an AI-driven digital health company with the mission to help patients with epilepsy live safer and more independently through AI-powered seizure prediction and monitoring," said Hassan Kotob, CEO of Mentis Care. "By combining the innovation capabilities of our partners, SK Biopharmaceuticals and Eurofarma, we aim to establish a new standard in digital epilepsy management for patients worldwide."

 

"For Eurofarma, the JV represents the future we envision for healthcare, combining digital technologies and medicines for a transformative and positive leap in patients' lives. We are a reference in central nervous system treatments in Latin America, with a broad portfolio of medicines and close relationships with psychiatrists and neurologists. For some years now, we have added digital innovation investments to our R&D activities, and since 2022, we have maintained a small operation in North America. With this new partnership, we will strengthen these fronts in a single move," says Rodrigo Pereira, Global Executive Director of Entrepreneurship and Digital at Eurofarma.

 

"SK Biopharmaceuticals is expanding beyond pharmaceuticals into digital healthcare to open new possibilities in patient care," said Donghoon Lee, CEO of SK Biopharmaceuticals. "Through Mentis Care, we will advance toward patient-centered innovation by integrating AI and clinical data to improve epilepsy treatment."

 

About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd.

SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, and combinatorial chemistry, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.SKLifeScienceInc.com.

SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea's second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit https://sk-inc.com/en/main/mainpage.aspx. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng.

 

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services aimed at improving people's quality of life. With a focus on generating shared value, the company covers key pharmaceutical segments such as prescription drugs, generics, hospital, oncology, OTC, personal care, and animal health, in addition to providing contract manufacturing services.

With broad coverage across therapeutic classes, its portfolio includes over 4,000 SKUs, serving nearly all medical specialties. Eurofarma is the leader in medical prescriptions in Brazil, where it also holds second place in the generics market. The company is present in 24 countries, with full coverage across Latin America and retail leadership in the region. It also maintains operations in the United States and Africa, with more than 13,500 employees and 11 manufacturing facilities. In 2024, Eurofarma produced 600 million units. That same year, the company invested over R$ 800 million in innovation projects and achieved net revenue exceeding R$ 11 billion.

 

About Mentis Care, Inc.
Mentis Care is an AI-driven health company transforming neurological care through the first predictive AI platform for brain health. The platform is designed to detect and forecast seizures and other neurological events in real time. By combining advanced machine learning with clinical expertise, Mentis Care aims to give patients and families greater safety, confidence, and peace of mind — while setting a new global standard in brain health and digital neuromonitoring.